PURE Bioscience Reports Fiscal Third Quarter 2025 Financial Results
MWN-AI** Summary
PURE Bioscience, Inc. (OTCQB: PURE) has released its financial results for the fiscal third quarter ending April 30, 2025. The company, renowned for its non-toxic antimicrobial solution, silver dihydrogen citrate (SDC), reported net product sales of $489,000, showing a modest increase from $440,000 in the same quarter of the previous year, reflecting growth within its distribution network.
Despite this rise in sales, the company reported a net loss of $580,000 for the quarter, an improvement compared to a loss of $857,000 in Q3 of 2024. When excluding share-based compensation, the net loss was reduced to $547,000 from $825,000 year-over-year. The net loss per share remained stable at ($0.01) for both periods.
For the first nine months of the fiscal year, net product sales totalled $1,435,000, down from $1,483,000 in the prior year, attributed to a decline in sales to end-users. The nine-month net loss decreased to $2,067,000 compared to $2,594,000 in 2024, with net loss per share improving from ($0.03) to ($0.02).
CEO Robert Bartlett remarked on the encouraging sales growth and operational cost reductions. He highlighted the successful deployment of their SDC technology in commercial dairy settings and emphasized plans to expand this technology into beverage industry applications. The introduction of PURE Hard Surface for membrane treatment marks a significant step, promising efficiency and cost savings for dairy and beverage manufacturers.
Overall, while sales challenges persist, PURE Bioscience is focused on innovation and strategic growth, enhancing its presence in the antimicrobial market. For detailed information, visit www.purebio.com.
MWN-AI** Analysis
PURE Bioscience (OTCQB: PURE) recently reported its fiscal third quarter financial results for 2025, revealing both challenges and opportunities within its business performance. The company's net product sales increased to $489,000, up from $440,000 in the same period last year, reflecting a solid growth trajectory in its distribution network. However, it is essential to note a decrease in net product sales for the nine months ended April 30, 2025, which totaled $1.435 million compared to $1.483 million in the previous year—signaling potential headwinds in maintaining broader market acceptance.
While the company recorded a net loss of $580,000 for the quarter—improved from a loss of $857,000 in Q3 2024—investors should cautiously track the company’s path to profitability as the operating loss remains significant. Management's focus on reducing operating expenses, reflected in lower selling and administrative costs, demonstrates prudent cost management but may also raise questions about operational scalability.
Additionally, PURE's foray into the dairy market using its silver dihydrogen citrate (SDC) technology shows promise. The introduction of PURE Hard Surface as a membrane treatment solution is particularly noteworthy, as it may enhance revenue streams by appealing to manufacturers focused on safety without sacrificing efficiency.
From an investment perspective, while there are glimmers of hope in sales growth and operational improvements, external factors, such as competitive pressures and customer acceptance of SDC products, remain critical for upcoming quarters. Investors should weigh these risks against the potential of the emerging markets targeted by PURE’s innovative products.
In summary, while PURE demonstrates positive trends and offers innovative solutions in its niche market, investors should approach with caution, closely monitoring future sales performance and expense management strategies as indicators of its longer-term viability and growth potential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2025.
Summary of Results of Operations – Fiscal Third Quarter
- Net product sales were $489,000 and $440,000 for the fiscal third quarter ended April 30, 2025 and 2024, respectively. The increase of $49,000 was attributable to increased sales across our distribution network.
- Net loss for the fiscal third quarter ended April 30, 2025 was $580,000, compared to $857,000 for the fiscal third quarter ended April 30, 2024.
- Net loss, excluding share-based compensation, for the fiscal third quarter ended April 30, 2025 was $547,000, compared to $825,000 for the fiscal third quarter ended April 30, 2024.
- Net loss per share was ($0.01) for the fiscal third quarters ended April 30, 2025 and 2024, respectively.
Summary of Results of Operations – Prior Nine Months
- Net product sales were $1,435,000 and $1,483,000 for the nine months ended April 30, 2025 and 2024, respectively. The decrease of $48,000 was attributable to decreased sales across our end-user network.
- Net loss for the nine months ended April 30, 2025 was $2,067,000, compared to $2,594,000 for the nine months ended April 30, 2024.
- Net loss, excluding share-based compensation, for the nine months ended April 30, 2025 was $1,950,000, compared to $2,418,000 for the nine months ended April 30, 2024.
- Net loss per share was ($0.02) and ($0.03) for the nine months ended April 30, 2025 and 2024, respectively.
Robert Bartlett, Chief Executive Officer, stated, “Our fiscal third quarter year-over-year sales growth continues to progress with our direct customers and distribution network, while we continue to reduce operating expenses. This quarter, we were able to demonstrate that our dairy membrane solution using our SDC technology is effective in full-scale commercial dairy plants. We will continue to work closely with our distribution partners in the beverage industry to expand this new membrane treatment solution.”
PURE Hard Surface is now available for membrane treatment. The transformative benefits of using PURE Hard Surface as a membrane treatment bring a more innovative and efficient approach, delivering measurable cost savings. This solution enables dairy and beverage manufacturers to maintain the highest quality standards in the industry, without the trade-offs associated with traditional chemistry. For more information, visit www.purebio.com/membrane .
About PURE Bioscience, Inc.
PURE is committed to redefining chemical safety through its innovative technology. With a focus on efficacy and effectiveness, PURE develops advanced solutions that meet the highest safety standards and produce best-in-class results for its consumers and distributors. PURE continues to focus on developing and commercializing our proprietary antimicrobial products, primarily in the food and beverage industry. We provide solutions to combat the health and environmental challenges posed by pathogens and ensure hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This broad-spectrum, non-toxic antimicrobial agent formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, and mitigation of bacterial resistance. Additional information on PURE is available at www.purebio.com .
Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release, including quotes from management, concerning the Company’s expectations, plans, business outlook, future performance, future potential revenues, expected results of the Company’s marketing efforts, the execution of contracts under negotiation, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE products into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2024, Form 10-Q for the fiscal first quarter ended October 31, 2024, Form 10-Q for the fiscal second quarter ended January 31, 2025, and Form 10-Q for the fiscal third quarter ended April 30, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
PURE Bioscience, Inc. Condensed Consolidated Balance Sheets | ||||||||
April 30, 2025 | July 31, 2024 | |||||||
(Unaudited) | ||||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 540,000 | $ | 349,000 | ||||
Accounts receivable | 287,000 | 298,000 | ||||||
Inventories, net | 131,000 | 56,000 | ||||||
Restricted cash | 75,000 | 75,000 | ||||||
Prepaid expenses | 13,000 | 27,000 | ||||||
Total current assets | 1,046,000 | 805,000 | ||||||
Property, plant and equipment, net | 11,000 | 13,000 | ||||||
Total assets | $ | 1,057,000 | $ | 818,000 | ||||
Liabilities and stockholders’ deficiency | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 799,000 | $ | 601,000 | ||||
Accrued liabilities | 173,000 | 132,000 | ||||||
Total current liabilities | 972,000 | 733,000 | ||||||
Long-term liabilities | ||||||||
Convertible notes payable to related parties | 4,899,000 | 2,949,000 | ||||||
Total long-term liabilities | 4,899,000 | 2,949,000 | ||||||
Total liabilities | 5,871,000 | 3,682,000 | ||||||
Commitments and contingencies | ||||||||
Stockholders’ deficiency | ||||||||
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding | — | — | ||||||
Common stock, $0.01 par value: 200,000,000 shares authorized, 111,856,473 shares issued and outstanding at April 30, 2025, and July 31, 2024 | 1,119,000 | 1,119,000 | ||||||
Additional paid-in capital | 132,729,000 | 132,612,000 | ||||||
Accumulated deficit | (138,662,000 | ) | (136,595,000 | ) | ||||
Total stockholders’ deficiency | (4,814,000 | ) | (2,864,000 | ) | ||||
Total liabilities and stockholders’ deficiency | $ | 1,057,000 | $ | 818,000 |
PURE Bioscience, Inc. Condensed Consolidated Statements of Operations (Unaudited) | ||||||||||||||||
Nine Months Ended | Three months Ended | |||||||||||||||
April 30, | April 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Net product sales | $ | 1,435,000 | $ | 1,483,000 | $ | 489,000 | $ | 440,000 | ||||||||
Royalty revenue | 3,000 | 6,000 | 2,000 | 1,000 | ||||||||||||
Total revenue | 1,438,000 | 1,489,000 | 491,000 | 441,000 | ||||||||||||
Cost of goods sold | 603,000 | 612,000 | 208,000 | 183,000 | ||||||||||||
Gross profit | 835,000 | 877,000 | 283,000 | 258,000 | ||||||||||||
Operating costs and expenses | ||||||||||||||||
Selling, general and administrative | 2,528,000 | 3,136,000 | 776,000 | 998,000 | ||||||||||||
Research and development | 243,000 | 233,000 | 91,000 | 77,000 | ||||||||||||
Total operating costs and expenses | 2,771,000 | 3,369,000 | 867,000 | 1,075,000 | ||||||||||||
Loss from operations | (1,936,000 | ) | (2,492,000 | ) | (584,000 | ) | (817,000 | ) | ||||||||
Other income (expense) | ||||||||||||||||
Other income (expense), net | 79,000 | 1,000 | 82,000 | 1,000 | ||||||||||||
Interest expense, net | (210,000 | ) | (103,000 | ) | (78,000 | ) | (41,000 | ) | ||||||||
Total other income (expense) | (131,000 | ) | (102,000 | ) | 4,000 | (40,000 | ) | |||||||||
Net loss | $ | (2,067,000 | ) | $ | (2,594,000 | ) | $ | (580,000 | ) | $ | (857,000 | ) | ||||
Basic and diluted net loss per share | $ | (0.02 | ) | $ | (0.03 | ) | $ | (0.01 | ) | $ | (0.01 | ) | ||||
Shares used in computing basic and diluted net loss per share | 111,856,473 | 111,856,473 | 111,856,473 | 111,856,473 |
PURE Bioscience, Inc. Condensed Consolidated Statement of Stockholders’ Equity (Deficiency) (Unaudited) | ||||||||||||||||||||||||||||||||||
Nine Months Ended April 30, 2025 | Nine Months Ended April 30, 2024 | |||||||||||||||||||||||||||||||||
Common Stock | Additional | Accumulated | Total | Common Stock | Additional | Accumulated | Total | |||||||||||||||||||||||||||
Shares | Amount | Capital | Deficit | Equity | Shares | Amount | Capital | Deficit | Equity | |||||||||||||||||||||||||
Balances at beginning of period | 111,856,473 | $ | 1,119,000 | $ | 132,612,000 | $ | (136,595,000 | ) | $ | (2,864,000 | ) | 111,856,473 | $ | 1,119,000 | $ | 132,398,000 | $ | (133,245,000 | ) | $ | 272,000 | |||||||||||||
Share-based compensation expense - stock options | — | — | 114,000 | — | 114,000 | — | — | 176,000 | — | 176,000 | ||||||||||||||||||||||||
Share-based compensation expense - restricted stock units | — | — | 3,000 | — | 3,000 | — | — | — | — | — | ||||||||||||||||||||||||
Net loss | — | — | — | (2,067,000 | ) | (2,067,000 | ) | — | — | — | (2,594,000 | ) | (2,594,000 | ) | ||||||||||||||||||||
Balances at end of period (Unaudited) | 111,856,473 | $ | 1,119,000 | $ | 132,729,000 | $ | (138,662,000 | ) | $ | (4,814,000 | ) | 111,856,473 | $ | 1,119,000 | $ | 132,574,000 | $ | (135,839,000 | ) | $ | (2,146,000 | ) |
Three Months Ended April 30, 2025 | Three Months Ended April 30, 2024 | |||||||||||||||||||||||||||||
Common Stock | Additional | Accumulated | Total | Common Stock | Additional | Accumulated | Total | |||||||||||||||||||||||
Shares | Amount | Capital | Deficit | Equity | Shares | Amount | Capital | Deficit | Equity | |||||||||||||||||||||
Balances at beginning of period (Unaudited) | 111,856,473 | $ | 1,119,000 | $ | 132,696,000 | $ | (138,082,000) | $ | (4,267,000) | 111,856,473 | $ | 1,119,000 | $ | 132,542,000 | $ | (134,982,000) | $ | (1,321,000) | ||||||||||||
Share-based compensation expense - stock options | — | — | 30,000 | — | 30,000 | — | — | 32,000 | — | 32,000 | ||||||||||||||||||||
Share-based compensation expense - restricted stock units | — | — | 3,000 | — | 3,000 | — | — | — | — | — | ||||||||||||||||||||
Net loss | — | — | — | (580,000) | (580,000) | — | — | — | (857,000) | (857,000) | ||||||||||||||||||||
Balances at end of period (Unaudited) | 111,856,473 | $ | 1,119,000 | $ | 132,729,000 | $ | (138,662,000) | $ | (4,814,000) | 111,856,473 | $ | 1,119,000 | $ | 132,574,000 | $ | (135,839,000) | $ | (2,146,000) |
PURE Bioscience, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||||||
Nine Months Ended | ||||||||
April 30, | ||||||||
2025 | 2024 | |||||||
Operating activities | ||||||||
Net loss | $ | (2,067,000 | ) | $ | (2,594,000 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Share-based compensation | 117,000 | 176,000 | ||||||
Depreciation | 2,000 | 110,000 | ||||||
Impairment of computer software | — | 60,000 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 11,000 | 51,000 | ||||||
Inventories | (75,000 | ) | 14,000 | |||||
Prepaid expenses | 14,000 | 17,000 | ||||||
Interest on note payable | 200,000 | 94,000 | ||||||
Accounts payable and accrued liabilities | 239,000 | 134,000 | ||||||
Net cash used in operating activities | (1,559,000 | ) | (1,938,000 | ) | ||||
Financing activities | ||||||||
Net proceeds from note payable to related parties | 1,750,000 | 1,285,000 | ||||||
Net cash provided by financing activities | 1,750,000 | 1,285,000 | ||||||
Net increase (decrease) in cash, cash equivalents, and restricted cash | 191,000 | (653,000 | ) | |||||
Cash, cash equivalents, and restricted cash at beginning of period | 424,000 | 1,170,000 | ||||||
Cash, cash equivalents, and restricted cash at end of period | $ | 615,000 | $ | 517,000 | ||||
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets | ||||||||
Cash and cash equivalents | $ | 540,000 | $ | 442,000 | ||||
Restricted cash | $ | 75,000 | $ | 75,000 | ||||
Total cash, cash equivalents and restricted cash | $ | 615,000 | $ | 517,000 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616907500/en/
Mark Elliott, VP Finance
PURE Bioscience, Inc.
Phone: 619-596-8600 ext. 116
FAQ**
How does Pure Bioscience Inc's (PURE) recent increase in net product sales affect its overall financial performance and future growth prospects in the food and beverage industry?
What strategies is Pure Bioscience Inc (PURE) implementing to address the decrease in net product sales over the past nine months, and what impact might this have on future profitability?
Given Pure Bioscience Inc (PURE)’s accumulated deficit, what measures are being taken to ensure long-term financial stability and reduce the reliance on external financing?
How does the performance of Pure Bioscience Inc (PURE)’s innovative solutions, such as the membrane treatment for dairy plants, influence its competitive position in the antimicrobial product market?
**MWN-AI FAQ is based on asking OpenAI questions about Pure Bioscience Inc (OTC: PURE).
NASDAQ: PURE
PURE Trading
3.54% G/L:
$0.0673 Last:
11,125 Volume:
$0.0599 Open:
